Ellenberger, David

[["dc.bibliographiccitation.firstpage","1641"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","1652"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Rommer, Paulus Stefan"],["dc.contributor.author","Eichstädt, Kerstin"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Pöhlau, Dieter"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe Klaus"],["dc.date.accessioned","2020-12-10T18:38:31Z"],["dc.date.available","2020-12-10T18:38:31Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1177/1352458518799580"],["dc.identifier.eissn","1477-0970"],["dc.identifier.issn","1352-4585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77349"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","173"],["dc.bibliographiccitation.journal","Multiple Sclerosis and Related Disorders"],["dc.bibliographiccitation.lastpage","174"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Eichstädt, Kerstin"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Pöhlau, Dieter"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe K"],["dc.contributor.author","Rommer, Paulus S"],["dc.date.accessioned","2020-12-10T15:20:23Z"],["dc.date.available","2020-12-10T15:20:23Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.msard.2018.07.040"],["dc.identifier.issn","2211-0348"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72654"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal - Experimental, Translational and Clinical"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Parciak, Tina"],["dc.contributor.author","Brola, Waldemar"],["dc.contributor.author","Hillert, Jan"],["dc.contributor.author","Middleton, Rod"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Thalheim, Christoph"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Ellenberger, David"],["dc.date.accessioned","2022-06-01T09:27:37Z"],["dc.date.available","2022-06-01T09:27:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background People with Multiple Sclerosis (PwMS) suffer from an increased risk of unemployment during the course of the disease. In recent years progress has been made in increasing the time until patients have to leave the workforce permanently. Such a retirement is often associated with MS but the driving factors including disability progression, support measures at the workplace, and societal aspects are not yet fully understood. Methods We consolidated data from four European MS databases from Germany, Poland, Sweden, and the United Kingdom, which were able to provide data on working status, disability progression and quality of life in accordance with the data harmonization framework of the EUReMS (European Registry in Multiple Sclerosis) project. Results Factors strongly associated with unemployment are disability progression, low quality of life and being close to the statutory retirement age. Overall, highest employment rate (77%) and lowest effects of gender and disease duration were found in Sweden. Conclusions We found remarkable differences between the European registers and the countries studied, which may indicate inequalities at European level. Furthermore, our findings suggest that it is feasible and useful to combine data from different MS registers in Europe, albeit the data structures are heterogeneous."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1177/20552173221090653"],["dc.identifier.pmid","35496757"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108532"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2055-2173"],["dc.relation.issn","2055-2173"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0/"],["dc.title","Comparison of employment among people with Multiple Sclerosis across Europe"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","436"],["dc.bibliographiccitation.issue","07"],["dc.bibliographiccitation.journal","Fortschritte der Neurologie · Psychiatrie"],["dc.bibliographiccitation.lastpage","450"],["dc.bibliographiccitation.volume","88"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Eichstädt, Kerstin"],["dc.contributor.author","Berger, Klaus"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Pöhlau, Dieter"],["dc.contributor.author","Rienhoff, Otto"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe K."],["dc.date.accessioned","2021-04-14T08:25:41Z"],["dc.date.available","2021-04-14T08:25:41Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1055/a-0985-4124"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81707"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1439-3522"],["dc.relation.issn","0720-4299"],["dc.title","Multiple Sklerose in Deutschland: aktualisierte Auswertungen des MS-Registers der DMSG 2014–2018"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","590"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Buckow, Karoline"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Heymann, D."],["dc.contributor.author","Mai, M."],["dc.contributor.author","Meissner, Thomas"],["dc.contributor.author","Zettl, Uwe K."],["dc.date.accessioned","2018-11-07T10:08:50Z"],["dc.date.available","2018-11-07T10:08:50Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Merck Serono; Biogen Idec; Bayer; Genzyme; Novartis; TEVA Sanofi"],["dc.identifier.isi","000383267202338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39545"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","The German MS Register: update on immunotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neurology and Therapy"],["dc.contributor.author","Frahm, Niklas"],["dc.contributor.author","Fneish, Firas"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Warnke, Clemens"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Parciak, Tina"],["dc.contributor.author","Krefting, Dagmar"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Stahmann, Alexander"],["dc.contributor.author","Zettl, Uwe K."],["dc.date.accessioned","2022-02-01T10:32:01Z"],["dc.date.accessioned","2022-08-18T12:41:03Z"],["dc.date.available","2022-02-01T10:32:01Z"],["dc.date.available","2022-08-18T12:41:03Z"],["dc.date.issued","2022-01-12"],["dc.date.updated","2022-07-29T12:18:29Z"],["dc.description.abstract","Abstract\r\n \r\n Introductions\r\n Therapy switches in patients with multiple sclerosis (MS) receiving treatment with fingolimod occur frequently in clinical practice but are not well represented in real-world data. The aim of this study was to identify and characterize treatment switches and reveal sociodemographic/clinical changes over time in fingolimod-treated people with MS (PwMS).\r\n \r\n \r\n Methods\r\n Data on 2536 fingolimod-treated PwMS extracted from the German MS Registry during different time periods were analyzed (2010–2019).\r\n \r\n \r\n Results\r\n Overall, 28.3% of PwMS were treatment-naïve before fingolimod initiation. Interferon beta (30.7%) was the most common pre-fingolimod treatment. Ocrelizumab (19.8%) was the most frequent subsequent treatment in the 944 patients on fingolimod who switched. Between 2010 and 2019, median disease duration at fingolimod initiation decreased from 8.5 to 7.1 years (p < 0.001), and patients taking fingolimod for ≥ 1 year after treatment initiation decreased from 89.6 to 80.5% (p < 0.001). Females (p < 0.001) and young patients (p = 0.003) showed a shorter time on fingolimod. The most frequent reason for switching was disease activity (relapse/MRI) despite treatment. The annualized relapse rate increased from 0.37 in patients on fingolimod to 0.47 after treatment cessation, decreasing to 0.19 after treatment with a subsequent disease-modifying drug (DMD) was initiated.\r\n \r\n \r\n Conclusion\r\n Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis."],["dc.identifier.doi","10.1007/s40120-021-00320-w"],["dc.identifier.pii","320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/99001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","Springer Healthcare"],["dc.relation.eissn","2193-6536"],["dc.relation.issn","2193-8253"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject","Multiple sclerosis"],["dc.subject","Fingolimod"],["dc.subject","Treatment switches"],["dc.subject","Rebound"],["dc.subject","Disease-modifying drug"],["dc.title","Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","13340"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Ohle, Lisa-Marie"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Flachenecker, Peter"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Haas, Judith"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Parciak, Tina"],["dc.contributor.author","Warnke, Clemens"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Stahmann, Alexander"],["dc.date.accessioned","2021-08-12T07:45:01Z"],["dc.date.available","2021-08-12T07:45:01Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract In 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of different healthcare sectors across Germany, GMSR provides observational real-world data on long-term disease progression, sociodemographic factors, treatment and the healthcare status of people with MS. This paper aims to illustrate the framework of the GMSR. Structure, design and data quality processes as well as collaborations of the GMSR are presented. The registry’s dataset, status and results are discussed. As of 08 January 2021, 187 centres from different healthcare sectors participate in the GMSR. Following its infrastructure and dataset specification upgrades in 2014, more than 196,000 visits have been recorded relating to more than 33,000 persons with MS (PwMS). The GMSR enables monitoring of PwMS in Germany, supports scientific research projects, and collaborates with national and international MS data repositories and initiatives. With its recent pharmacovigilance extension, it aligns with EMA recommendations and helps to ensure early detection of therapy-related safety signals."],["dc.description.abstract","Abstract In 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of different healthcare sectors across Germany, GMSR provides observational real-world data on long-term disease progression, sociodemographic factors, treatment and the healthcare status of people with MS. This paper aims to illustrate the framework of the GMSR. Structure, design and data quality processes as well as collaborations of the GMSR are presented. The registry\\’s dataset, status and results are discussed. As of 08 January 2021, 187 centres from different healthcare sectors participate in the GMSR. Following its infrastructure and dataset specification upgrades in 2014, more than 196,000 visits have been recorded relating to more than 33,000 persons with MS (PwMS). The GMSR enables monitoring of PwMS in Germany, supports scientific research projects, and collaborates with national and international MS data repositories and initiatives. With its recent pharmacovigilance extension, it aligns with EMA recommendations and helps to ensure early detection of therapy-related safety signals."],["dc.identifier.doi","10.1038/s41598-021-92722-x"],["dc.identifier.pii","92722"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88352"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.relation.eissn","2045-2322"],["dc.title","Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]